SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Divest Entire Stake in Immix Biopharma

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, reporting a 0% beneficial ownership stake in Immix Biopharma, Inc., indicating a complete divestment of their previous holdings.

Summary

• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous beneficial ownership report.
• The reporting persons are Orin Hirschman, AIGH Capital Management LLC, and AIGH Investment Partners, L.L.C.
• The issuer is Immix Biopharma, Inc., with its principal executive offices located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA, 90064.
• The class of securities is Common Stock, with CUSIP Number 45258H106.
• As of the event date, the aggregate amount beneficially owned by each reporting person is 0.00 shares, representing 0% of the class.
• The reporting persons certify that the securities were acquired and held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment of shares by AIGH Capital Management LLC and Orin Hirschman indicates a negative sentiment from these investors regarding Immix Biopharma, Inc.

Negatives

• AIGH Capital Management LLC and Orin Hirschman, who previously held a beneficial ownership stake (implied by the 'Amendment No. 1' filing), have now reported 0% ownership, indicating a complete divestment of their holdings in Immix Biopharma, Inc.
• This complete divestment by institutional investors could be perceived negatively by the market, potentially signaling a lack of confidence in the company's future prospects.

Future Outlook

NA

Industry Context

This filing reflects a change in an institutional investor's position, which can influence market perception within the biopharma industry, particularly for smaller companies like Immix Biopharma. A significant divestment by an institutional holder can lead to increased scrutiny from other investors.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential share price decline due to the complete divestment by a significant institutional investor.

Key Dates

Recommendation

Keywords

Immix Biopharma, AIGH Capital Management, Orin Hirschman, Schedule 13G, Beneficial Ownership, Common Stock, Divestment, SEC Filing, Investment